Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VT1S
|
|||
| Former ID |
DCL000253
|
|||
| Drug Name |
TTP889
|
|||
| Synonyms |
VP-14637; VP 14637; 235106-62-4; (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol); MDT-637; AC1O5AXS; CHEMBL3393516; SCHEMBL20741449; SCHEMBL16743389; CHEMBL3393661; (4E)-2-[(4-hydroxyphenyl)-[(3E)-3-[[(5-methyltetrazol-1-yl)amino]methylidene]-6-oxocyclohexa-1,4-dien-1-yl]methyl]-4-[[(5-methyltetrazol-1-yl)amino]methylidene]cyclohexa-2,5-dien-1-one; DB12195; ACM235106624; J-015135
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Blood forming organ disorder [ICD-11: JB64.1; ICD-10: O99.1] | Phase 2 | [1] | |
| Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Terminated | [2] | ||
| Company |
TransTech Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22N10O3
|
|||
| Canonical SMILES |
CC1=NN=NN1N=CC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)O)C4=C(C=CC(=C4)C=NN5C(=NN=N5)C)O
|
|||
| InChI |
1S/C25H22N10O3/c1-15-28-30-32-34(15)26-13-17-3-9-23(37)21(11-17)25(19-5-7-20(36)8-6-19)22-12-18(4-10-24(22)38)14-27-35-16(2)29-31-33-35/h3-14,25,36-38H,1-2H3/b26-13+,27-14+
|
|||
| InChIKey |
BLUJRJMLDHEMRX-BMNRKXRESA-N
|
|||
| CAS Number |
CAS 235106-62-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor IX (F9) | Target Info | Inhibitor | [1], [3] |
| Measles virus Fusion glycoprotein (MeV F) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63. | |||
| REF 2 | Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. | |||
| REF 3 | Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs. 2006;66(11):1411-29. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.